Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA)

CUSIP: 877619106

Q4 2022 13F Holders as of 31 Dec 2022

Holder snapshot 7 signals
Share change
+5,401,271
Put/Call ratio
68%
SEC-reported price per share
$2.26
Number of holders
51
Value change
+$12,385,904
Number of buys
31
Open additional details 1 more signal available
Number of sells
23
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
332,184,263

Security key

877619106

Report period

Q4 2022

Institutions

51

Top holders

10

Ownership snapshot

Top reported holders of TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Audentes Therapeutics, Inc.
Disclosed value leader
Audentes Therapeutics, Inc.
Comparable rows
0/15
Latest evidence
21 Oct 2022
3/4/5 13F Highest disclosed value: $11,844,137 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Audentes Therapeutics, Inc. has the largest disclosed position value at $11.84M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Audentes Therapeutics, Inc.'s linked filing trail.
Disclosed position value Top 5
Audentes Therapeutics, Inc. $11.84M
Nantahala Capital Management, LLC $3.25M
VANGUARD GROUP INC $2.07M
Artal Group S.A. $2.01M
BlackRock Finance, Inc. $2M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Audentes Therapeutics, Inc.
3/4/5
10%+ Owner
—
denominator unverified
$11,844,137
7,266,342 shares
— 21 Oct 2022
Nantahala Capital Management, LLC
13F
Company
13F
—
denominator unverified
$3,246,000
1,610,822 shares
— 30 Sep 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$2,067,000
1,070,802 shares
— 30 Sep 2022
Artal Group S.A.
13F
Company
13F
—
denominator unverified
$2,009,000
1,040,882 shares
— 30 Sep 2022
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$1,999,000
1,035,649 shares
— 30 Sep 2022
FRANKLIN TEMPLETON INC
13F
Company
13F
—
denominator unverified
$1,565,000
811,069 shares
— 30 Sep 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
51
Shares
19,375,255
Rows available
51
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders
48
Q4 2022 holders
51
Holder diff
3
Investor Q3 2022 Shares Q4 2022 Shares Share Diff Share Chg % Q3 2022 value Q4 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .